An enzyme known as tissue plasminogen activator (tPA) is connected to the breakdown of blood clots. A serine protease, it can be found in endothelial cells. The transformation of plasminogen into plasmin is catalyzed by serine protease. Serine protease is a key enzyme in the dissolution of clots.The first and only medication authorized by the American FDA in 1996 for the treatment of acute ischemic stroke is tissue plasminogen activator. During the anticipated period, the market expansion is anticipated to be fueled by the rising incidence of stroke.
The global Tissue Plasminogen Activator Market is estimated to be valued at US$ 2,455.4 million in 2022 and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).
Major Players in the Tissue Plasminogen Activator Industry
1. F. Hoffmann-La Roche AG,
F. Hoffmann-La Roche AG, was founded in 1896 and it’s headquarter in Basel, Switzerland .The Company operates in 140 countries. F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare.
2. Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH, was launch in 1885. And it’s headquarter - Ingelheim am Rhein, Germany. It operate over 100 country Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth.